AI assistant
Sending…
Spyre Therapeutics, Inc. — Director's Dealing 2017
Jun 15, 2017
32226_dirs_2017-06-14_6c6f2400-6b50-4e8c-8fb5-526dfc1f35c6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2017-05-22
Reporting Person: Schuchart Aaron (Chief Business Officer)
More from Spyre Therapeutics, Inc.
Regulatory Filings
2026
Jun 1
Declaration of Voting Results & Voting Rights Announcements
2026
May 29
Regulatory Filings
2026
May 5
Interim / Quarterly Report
2026
May 5
Regulatory Filings
2026
Apr 16
Capital/Financing Update
2026
Apr 13
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 13
Proxy Solicitation & Information Statement
2026
Apr 10
Major Shareholding Notification
2026
Mar 27